Inhibition of ACSL4 Alleviates Parkinsonism Phenotypes by Reduction of Lipid Reactive Oxygen Species

Area of Science:

• Neuroscience
• Cell Biology
• Biochemistry

Background:

• Ferroptosis, a programmed cell death pathway, is increasingly implicated in Parkinson's disease (PD) pathogenesis.
• Key molecular drivers of ferroptosis in PD, particularly within the substantia nigra, remain incompletely understood.

Purpose of the Study:

• To investigate the role of Acyl-CoA synthetase long-chain family member 4 (ACSL4) in ferroptosis-associated neurodegeneration in Parkinson's disease.
• To evaluate ACSL4 as a potential therapeutic target for PD.

Main Methods:

• Assessed ACSL4 expression in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD and in post-mortem PD patient substantia nigra samples.
• Utilized genetic knockdown of ACSL4 and pharmacological inhibition with Triacsin C in MPTP-treated mice and 1-methyl-4-phenylpyridinium (MPP+) treated cells.
• Measured dopaminergic neuronal survival, motor function, and reactive oxygen species (ROS) levels (lipid and mitochondrial).

Main Results:

• ACSL4 expression was elevated in the substantia nigra of MPTP-treated mice and in PD patients.
• Knockdown or inhibition of ACSL4 conferred significant protection against dopaminergic neuronal loss and motor impairments in the PD model.
• ACSL4 reduction specifically mitigated lipid peroxidation-induced reactive oxygen species (ROS) elevation, without impacting mitochondrial ROS.

Conclusions:

• ACSL4 plays a critical role in mediating ferroptosis and subsequent dopaminergic neurodegeneration in Parkinson's disease.
• Targeting ACSL4, a key mediator of lipid peroxidation, represents a promising therapeutic strategy for Parkinson's disease.